Chimeric antigen receptor T-cell therapies in acute myeloid leukaemia
CARs have produced remarkable outcomes in relapsed and refractory B-cell malignancies. However, replicating this success in acute myeloid leukaemia (AML) is not straightforward.
Expert Opinion Articles
CAR T cell therapy for multiple myeloma
Autologous CAR T cells targeting BCMA are undergoing clinical trials and early results are promising, including in patients who have received a substantial amount of treatment for myeloma over many years and typically do not respond to new therapies.
CAR T cell therapy for solid tumours
The dramatic success achieved using chimeric antigen receptor (CAR) T cells in haematological malignancies has prompted concerted efforts to apply the same technology in solid tumours.